Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081926 | 1.00 | ELANE (0.32) | ELANECTRB1GAALMNANPSR1 | |
| SCHEMBL8318115 | 1.00 | ELANE (0.32) | ELANECTRB1GAALMNANPSR1 | |
| SCHEMBL6081857 | 0.83 | — | — | |
| SCHEMBL6081994 | 0.83 | — | — | |
| SCHEMBL8317430 | 0.76 | CYP4F2 (0.44) | — | |
| SCHEMBL8313320 | 0.73 | POLB (0.34) | ELANECTRB1LMNANPSR1BRD9 | |
| SCHEMBL6083239 | 0.73 | POLB (0.34) | ELANECTRB1LMNANPSR1BRD9 | |
| SCHEMBL6081924 | 0.73 | POLB (0.34) | ELANECTRB1LMNANPSR1BRD9 | |
| SCHEMBL8313324 | 0.73 | ELANE (0.33) | ELANECTRB1 | |
| SCHEMBL27396218 | 0.72 | ELANE (0.37) | ELANECTRB1GAALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030245-B2 | Antidepressant azahetorocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenathrene | WYETH (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050228010-A1 | Antidepressant azahetorocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | WYETH (US) | 2005-10-13 | — | — | US | disclosed |
| US-6930109-B2 | Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-6903110-B2 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040235851-A1 | Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | WYETH | 2004-11-25 | — | — | US | disclosed |
| US-20030078268-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | WYETH (US) | 2003-04-24 | — | — | US | disclosed |
| WO-2003010169-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7, 8-DIHYDRO-6H-5-OXA-1-AZA-PHENANTHRENE | WYETH (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078268-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | TPH1, CYP19A1, HSD3B1 | ELANE 3378/4885CTRB1 3802/4885GAA 419/4885 |
| US-20040235851-A1 | Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | TPH1, CYP19A1, HSD3B1 | ELANE 3469/4885CTRB1 3927/4885GAA 578/4885 |
| US-20050228010-A1 | Antidepressant azahetorocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene | HTR5A, TPH1, CYP19A1 | ELANE 3138/4885CTRB1 3931/4885GAA 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.